Management of Sexual Partners of Patients with HSV-2
Sexual partners of HSV-2 infected patients should undergo type-specific HSV-2 serologic testing to determine their infection status, and if seronegative, the infected partner should be offered daily suppressive antiviral therapy to reduce transmission risk. 1
Partner Testing Strategy
The 2021 CDC guidelines specifically recommend HSV-2 serologic testing for persons who are at increased epidemiologic risk, explicitly including sexual partners of individuals with genital HSV-2 infection 1. This testing serves two critical purposes:
- Identifies undiagnosed symptomatic infection in the partner who may have attributed symptoms to other causes
- Establishes serodiscordant couples where transmission prevention strategies are most beneficial 2
Testing Considerations
When testing partners, be aware of serologic test limitations:
- Use index values ≥3.0 on HerpeSelect for diagnosis without confirmatory testing 1
- For lower index values (particularly with HSV-1), confirm with a second method like Biokit HSV-2 rapid assay, which improves specificity from 93.2% to 98.7% 1
- False positives can occur even at index values >3.5, though this is uncommon 1
Transmission Prevention for Serodiscordant Couples
For couples where one partner has HSV-2 and the other tests negative, implement a multi-component prevention strategy:
1. Suppressive Antiviral Therapy (Primary Intervention)
The infected partner should be offered daily suppressive therapy 1. While studied primarily in heterosexual couples, the mechanism works through suppression of viral shedding, which is biologically relevant across all populations 1. Standard suppressive regimens include:
- Valacyclovir 500mg daily
- Acyclovir 400mg twice daily
- Famciclovir 250mg twice daily
2. Behavioral Modifications
- Avoid sexual contact during symptomatic outbreaks 3
- Consistent condom use reduces but does not eliminate transmission risk 3
- Recognize that asymptomatic viral shedding is the most frequent mode of transmission 4
Counseling the Uninfected Partner
The uninfected partner needs comprehensive education about:
- Natural history: HSV-2 is a lifelong infection with variable viral shedding even without symptoms 3
- Transmission risk: Occurs even during asymptomatic periods, though suppressive therapy significantly reduces this risk
- Recognition of symptoms: Many infections are initially asymptomatic or attributed to other causes 4
- Testing limitations: Serologic tests may take 3-6 months after exposure to become positive
When Partner Testing is Most Valuable
Type-specific serology demonstrates particular clinical utility in partner management:
- Makes a diagnosis in 27% of men and 50% of women with HSV-2 positive partners 5
- Provides counseling value in 50% of women and 73% of men in serodiscordant relationships 5
- Helps identify those who would benefit most from suppressive therapy in the infected partner 2
Common Pitfalls to Avoid
- Don't rely on clinical diagnosis alone - laboratory confirmation is essential for accurate partner counseling 6
- Don't assume the partner is uninfected - up to 50% of partners may already be HSV-2 positive but unaware 5
- Don't test too early after exposure - allow adequate time for seroconversion (typically 3-6 months)
- Don't screen low-risk asymptomatic individuals - USPSTF recommends against general population screening, but partners of infected individuals are high-risk and warrant testing 1